Leflunamide use in the treatment of rheumatoid arthritis in the patient with end stage chronic renal insufficiency at the background of secondary AA amyloidosis


Cite item

Full Text

Abstract

Renal impairment substantially limits the choice of basal antirheumatic therapy (BART) of rheumatoid arthritis (RA). Elderly age and presence of renal disease on the background of a long course of RA are the risk factors for side effects of BART. Thus, rheumatologist in practice often solve nonconventional challenge of searching the golden mean between the need for early initiation of aggressive BART and minimizing the risk of adverse effects against the background of its administration. Leflunomide is a unique basis antirheumatic drug, which can be used in patients with chronic renal insufficiency, including those on program hemodialysis.

References

  1. Демина А.Б., Раденска-Лоповок С.Г., Фоломеева О.М., Эрдес Ш. Причина смерти больных с ревматическими заболеваниями в Москве. Тер. архив 2005. № 77(4). C. 77-82.
  2. Bely M, Apathy A. Causes of death as well as complications in rheumatoid arthritis. Orv Hetil 1994;135(37):2029-34.
  3. Проблема ревматоидной нефропатии // Тер. архив 2003. № 75(5). C. 24-9. Icardi A, Araghi P, Ciabattoni M, et al. Coinvolgimento renale in corso di artrite reumatoide. Reumatismo 2003;55(2):76-85.
  4. Клиническая нефрология / Под редакцией Е.М. Тареева. М., 1983. Т. 2.
  5. Hezemans RL, Krediet RT, Arisz L. Dialysis treatment in patients with rheumatoid arthritis. Neth J Med. 1995;47(1):6-11.
  6. Насонов Е.Л. Метотрексат: перспективы применения в ревматологии. М., 2005.№ 24(25).C. 57-117.
  7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. J Rheumatol 2000;27(7):1648-55.
  8. Combe B, Kinowski JM, Bologna C, et al. Effects of renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Arthritis Rheum 1997;40:94.
  9. Чупрасов В.Б. Программный гемодиализ. СПБ, 2001.
  10. Ассоциация ревматологов России. Клинические рекомендации "Лечение ревматоидного артрита". М., 2004.
  11. Zelinski T, Muller HJ, Scheyerbach R, et al. Differential effects of leflunomide on leucocytes: inhibition of rat in vivo adhesion and human in vitro oxidative burst without affecting surface marker modulation. Agents Actions 1994;41:276-78.
  12. Lang R, Wagner H, Heeg K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo: Leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T-cell-mediated shock. Transplantation 1995;59:382-89.
  13. Iwamoto M, Homma S, Asano Y, et al. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol 2005;34(5):410-11.
  14. Насонов Е.Л. Диагностика и лечение ревматоидного артрита. Клинические рекомендации. Ревматология. М., 2006. C. 35.
  15. Migita K, Miyashita T, Mayeda Y, et al. An active metabolite of leflunomide, A771726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology 2005;44:443-48.
  16. Baumann Ph, Mandl-Weber S, Adam C, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009;8(2):366-75.
  17. Prakash A, Jarvis B. Leflunomide; review of its use in active rheumatoid arthritis. Drugs 1999;58(6):1137-64.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies